진행성 비소세포 폐암환자에서의 5-Fluorouracil, Ifosfamide와 Cisplatin(FIP) 복합화학요법
5-Fluorouracil, Ifosfamide, and Cisplatin(FIP) Combination Chemotherapy for Advanced Non-Small Cell Lung Cancer
대한암학회지 1995년 27권 2호 p.284 ~ 291
소속 상세정보
서영일
박영석/이재명/최조영/김현수/조병동/서유미/한윤창/김호중
KMID : 0360319950270020284
Abstract
We conducted a phase Ⅱtrial of combining 5-fluorouracil(5-FU), ifosfamide(IFM), and cisplatin(DDP) in previously untreated patients with advanced, unresectable, non-small cell lung cancer(NSCLC). Each cycle consisted of 5-FU 100mg/m* i. v. day
1.
Cycles were repeated at 3 week intervals.
Twenty eight patients were enrolled. Age ranged from 36 to 73(median 57 years); 24 were male, 4 female. Eleven patients had stage Ⅲb disease and 17 stage Ⅳ. Two patients were not evaluable because of lost to follow up. None had a complete
response, 13
patients(50%)had partial responses, 8(31%) had stable diseases, and 5(19%) had progressive diseases. The median response duration was 11.2 weeks; the median time to progression was 12 weeks. The overall median survival was 19 weeks(27.5 weeks for
responders, 12.8 weeks for non-responders). Major side effects were alopecia, nausea/vomiting and stomatitis, all of which were well tolerated and reversible. By univariate analysis, stage and performance status correlated with time to
progression
and
overall survival time.
In conclusion, FIP combination chemotherapy for patients with advanced, unresectable non-small cell lung cancer seems to be an effective and well-tolerated regimen.
키워드
원문 및 링크아웃 정보
등재저널 정보